The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia
Hematological Oncology · 2025
DOI: 10.1002/hon.70116 ↗Kurz gefasst
Leserbrief in der Zeitschrift Hematological Oncology, 2025. Verfasst von Xiaoyu Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, National Clinical Research Center for Blood Diseases, Institute …. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Mitoxantrone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Despite allo‐HSCT being the primary curative treatment for high‐risk AML, relapse‐free survival (RFS) remains suboptimal due to high relapse incidence. Our research focuses on optimizing the conditioning regimen by incorporating Mitoxantrone Hydrochloride Liposome (Lipo‐MIT), a novel nano‐formulation with enhanced pharmacokinetic properties and demonstrated anti‐leukemic efficacy. Preclinical studies have shown that Lipo‐MIT significantly improves survival outcomes compared to conventional mitoxantrone, and our study aims to translate these findings into clinical practice. In this study, we present the results of a Lipo‐MIT as part of the conditioning regimen for high‐risk AML patients undergoing allo‐HSCT. Our findings highlight the potential of Lipo‐MIT to improve RFS, while also providing insights into patient selection and the refinement of Lipo‐MIT‐based conditioning strategies. We believe this work contributes valuable knowledge to the field and has the potential to impact clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Tianjin Institutes of Health Science, Tianjin, China.
ORCID-Profile: Yi He, Erlie Jiang
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Zhang, X., Yang, D., Pang, A., Feng, S., Han, M., He, Y., & Jiang, E. (2025). The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia. Hematological Oncology. https://doi.org/10.1002/hon.70116
Vancouver
Zhang X, Yang D, Pang A, Feng S, Han M, He Y, et al. The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia. Hematological Oncology. 2025. doi:10.1002/hon.70116
BibTeX
@article{Zhang2025,
author = {Zhang, Xiaoyu and Yang, Donglin and Pang, Aiming and Feng, Sizhou and Han, Mingzhe and He, Yi and Jiang, Erlie},
title = {The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70116}
}
EUVIMED